This Thorough-QT (TQT) study in healthy volunteers will be conducted in two phases. Phase One (n=15) will be used to identify a safe supratherapeutic dose to be used in the TQT study (Phase Two). Phase Two will be a randomized, placebo and positive-controlled, 4-way crossover TQT study. Thirty-two subjects will receive all 4 of the following treatments in randomized sequence.~meropenem-vaborbactam 4 g (meropenem 2 g- vaborbactam 2 g) therapeutic dose infused intravenously over 3 hours~meropenem-vaborbactam supratherapeutic dose to be determined infused intravenously over 3 hours.~Placebo (normal saline) to match meropenem-vaborbactam volume infusion over 3 hours~Moxifloxacin 400 mg positive control (oral; open-label)
This Thorough-QT (TQT) study in healthy volunteers will be conducted in two phases. Phase One will be used to identify a safe supratherapeutic dose to be used in the TQT study (Phase Two). Phase Two will be a 4-way crossover TQT study. Thirty-two subjects will receive all 4 of the following treatments in randomized sequence.~meropenem-vaborbactam 4 g (meropenem 2 g- vaborbactam 2 g) therapeutic dose infused intravenously over 3 hours~meropenem-vaborbactam supratherapeutic dose to be determined infused intravenously over 3 hours.~Placebo (normal saline) to match meropenem-vaborbactam volume infusion over 3 hours~Moxifloxacin 400 mg positive control (oral; open-label)